Renessans Q2 2026: Revenue Growth Holds at 9.2% but Profit Swings to Loss

Renessans reported Q2 2026 revenue of 28,247.3 mln, up 9.2% y/y, while net profit swung to a loss of 701.0 mln from a 2,958.1 mln profit a year earlier (-123.7% y/y). Revenue growth was broadly stable versus the previous half (H1 2026: +8.5%), with no acceleration in the top line; profitability deteriorated sharply, with the loss in Q2 matching the Q1 2026 loss of 701.0 mln and H1 2026 net loss reaching 1,402.1 mln.

Q2 2026 vs Q2 2025: headline y/y growth

What drove the result

The top line continued to expand, but the swing to a net loss of 701.0 mln from a 2,958.1 mln profit implies a severe margin squeeze: the net margin moved from roughly 11.4% in Q2 2025 (2,958.1/25,862.2) to about -2.5% in Q2 2026 (-701.0/28,247.3). With no EBITDA or cost breakdown disclosed, the driver cannot be isolated, but the magnitude of the profit decline relative to modest revenue growth points to cost inflation or one-off charges rather than a demand problem. Equity slipped to 53,911.1 mln from 54,200 mln a year earlier, consistent with losses eroding the capital base.

Key figures

Outlook

The key question is whether the loss is a one-off or a structural margin issue. The Q1 2026 loss of 701.0 mln was repeated exactly in Q2 2026, suggesting a persistent cost or impairment drag rather than a single-quarter event. With H1 2026 revenue at 100,000 mln and net loss at 1,402.1 mln, the second half must deliver a sharp profitability recovery to avoid a full-year loss. No guidance or dividend update was provided in the disclosed facts.

What to watch: the absence of an EBITDA line and cost breakdown limits visibility, so the next disclosure should clarify whether the loss stems from operating costs, provisions, or non-recurring items. Revenue growth of 9.2% is respectable but insufficient to offset the margin collapse; without a credible path back to profitability, the equity base (53,911.1 mln) will continue to erode. Investors should focus on management commentary on cost control and any asset-quality or impairment signals.